The development of molecules embedding two distinct pharmacophores acting as
muscarinic antagonists and β2 agonists (MABAs) promises to be an excellent opportunity to …

Clinical guidelines for COPD and asthma recommend inhaled β-adrenergic agonists,
muscarinic antagonists, and, for frequent exacerbators, inhaled corticosteroids, with the …

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in the
world today. Bronchodilators, particularly muscarinic antagonists and β2 agonists, are …

The targeting of both the muscarinic and β-adrenergic pathways is a well validated
therapeutic approach for the treatment of chronic obstructive pulmonary disease (COPD). In …

We sought to design dual pharmacology bronchodilators targeting both the M3 muscarinic
acetylcholine and beta-2 adrenergic (β2) receptors by applying our multivalent approach to …

The use of muscarinic receptor antagonists in the treatment of chronic obstructive pulmonary
disease (COPD) is well established. More recently, the potential for long-acting muscarinic …

Abstract Inhaled beta-2-adrenergic receptor (β 2) agonists and inhaled muscarinic
acetylcholine antagonists are the most frequently used bronchodilators in the treatment of …

Through application of our multivalent approach to drug discovery we previously reported
the first discovery of dual pharmacology MABA bronchodilators, exemplified by 1. Herein we …

LAS190792 is a novel muscarinic antagonist and β 2-adrenoceptor agonist in development
for chronic respiratory diseases. This study investigated the pharmacological profile of …

Combinations of a muscarinic receptor antagonist (MA) and a β2-adrenoceptor agonist (BA)
improve bronchodilation in COPD patients to a greater extent than drugs with either …